A new oral drug for type 2 diabetes helped patients lose significant weight in a global trial.
Researchers tested orforglipron against oral semaglutide over one year.
The pill activates GLP-1 receptors to lower blood sugar and reduce appetite.
Patients can take it without fasting, which simplifies daily use.
More than 1,500 adults joined the study across five countries.
Participants taking orforglipron lost up to eight percent of their body weight.
Those on semaglutide lost about five percent.
The new drug also improved average glucose levels more strongly.
However, more patients stopped treatment because of stomach-related side effects.
Regulators still review orforglipron for approval.
Experts believe effective tablets could widen access to obesity and diabetes care.
They expect future therapies to target weight, metabolism, and heart risk together.
